Company / Cost of Revenue
ACCENDRA HEALTH INC/VA/ Cost of Revenue History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cost of Revenue
$1.5B
FY2025
5-year range
$1.3B / $8.1B
FY2021-FY2025
Trend
+5.2%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cost of Revenue has fluctuated over the past 10 years, ranging from $1.3B in FY2023 to $8.5B in FY2016.
Based on SEC 10-K filings.
$1.5B in FY2025 with a 5-year CAGR of -27.2%.
Increased from $1.3B to $1.5B over the past 2 years.
Cost of Revenue over time
Growth rates
- 3-Year CAGR
- -43.4%
- 5-Year CAGR
- -27.2%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -27.2%, indicating a declining trend.
- In FY2025, cost of revenue increased 5.2% year-over-year.
- Peak cost of revenue was recorded in FY2016.
- Lowest cost of revenue in the period was in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 0.60 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cost of RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.5B | +5.2% |
| FY2024 | $1.4B | +4.8% |
| FY2023 | $1.3B | -83.6% |
| FY2022 | $8.1B | +0.6% |
| FY2021 | $8.1B | +12.3% |
| FY2020 | $7.2B | -13.8% |
| FY2019 | $8.3B | +0.0% |
| FY2018 | $8.3B | +2.5% |
| FY2017 | $8.1B | -4.6% |
| FY2016 | $8.5B | -0.3% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026